Wealth Enhancement Advisory Services’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$475K Buy
81,811
+7,331
+10% +$35.8K ﹤0.01% 2735
2026
Q1
$328K Buy
74,480
+12,085
+19% +$67.3K ﹤0.01% 2682
2025
Q4
$530K Sell
62,395
-1,163
-2% -$7.2K ﹤0.01% 2429
2025
Q3
$233K Buy
63,558
+32,639
+106% +$88.9K ﹤0.01% 2994
2025
Q2
$64.6K Buy
+30,919
New +$64.4K ﹤0.01% 3198
2025
Q1
Sell
-10,140
Closed -$27K 3100
2024
Q4
$27K Buy
+10,140
New +$26.1K ﹤0.01% 2894

Other funds holding NUVB

Wealth Enhancement Advisory Services's NUVB Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Nuvation Bio (NUVB) stake by 9.8% in Q2 2026, buying an estimated $35.8K and bringing the position to 81,811 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Wealth Enhancement Advisory Services first reported a position in NUVB in Q4 2024 and has held it in 6 quarters since. The position peaked at $530K in Q4 2025. 13 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Wealth Enhancement Advisory Services held 81,811 shares of Nuvation Bio worth $475K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 7,331 Nuvation Bio shares in Q2 2026, an estimated $35.8K.
  • Nuvation Bio made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2735 holding.
  • Wealth Enhancement Advisory Services first reported a position in Nuvation Bio in Q4 2024 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Nuvation Bio position peaked at $530K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.